共 50 条
- [1] A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)Shah, Manish A.Metges, Jean-PhilippeCunningham, DavidShiu, Kai-KeenWyrwicz, LucjanThai, DungBrachmann, CarrieBhargava, PankajCatenacci, Daniel V. T.Wainberg, Zev A.
- [2] CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Feeney, KynanKelly, RonanLipton, Lara RachelChao, JosephAcosta-Rivera, MirelisEarle, DennisLei, MingKollia, GeorgiaTebbutt, Niall C.
- [3] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialLANCET ONCOLOGY, 2020, 21 (12): : 1574 - 1588Powles, Thomasvan der Heijden, Michiel S.Castellano, DanielGalsky, Matthew D.Loriot, YohannPetrylak, Daniel P.Ogawa, OsamuPark, Se NoonLee, Jae-LyunDe Giorgi, UgoBogemann, MartinBamias, AristotelisEigl, Bernhard J.Gurney, HowardMukherjee, Som D.Fradet, YvesSkoneczna, IwonaTsiatas, MarinosNovikov, AndreySuarez, CristinaFay, Andre P.Duran, IgnacioNecchi, AndreaWildsmith, SophieHe, PhilipAngra, NatashaGupta, Ashok K.Levin, WendyBellmunt, Joaquim
- [4] A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Shah, Manish A.Metges, Jean-PhilippeChun, Patrick YoungwhanSmith, VictoriaMaltzman, Julia D.Wainberg, Zev A.
- [5] Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS484 - TPS484Lee, Keun-WookMoehler, Markus H.Cunningham, DavidWainberg, Zev A.Uronis, Hope ElizabethOh, Do-YounKim, In-HoShim, Byoung YongSym, Sun JinAltura, Rachel A.Stilian, Melissa C.Parker, Elizabeth C.Klempner, Samuel J.
- [6] Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)ESOPHAGUS, 2021, 18 (01) : 90 - 99Takahashi, MasanobuKato, KenOkada, MorihitoChin, KeishoKadowaki, ShigenoriHamamoto, YasuoDoki, YuichiroKubota, YutaroKawakami, HisatoOgata, TakashiHara, HirokiMuto, ManabuNakashima, YuichiroIshihara, RyuTsuda, MasahiroMotoyama, SatoruKodani, MamoruKitagawa, Yuko
- [7] Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)Esophagus, 2021, 18 : 90 - 99Masanobu TakahashiKen KatoMorihito OkadaKeisho ChinShigenori KadowakiYasuo HamamotoYuichiro DokiYutaro KubotaHisato KawakamiTakashi OgataHiroki HaraManabu MutoYuichiro NakashimaRyu IshiharaMasahiro TsudaSatoru MotoyamaMamoru KodaniYuko Kitagawa
- [8] Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 312 - 312Peng, ZhiZhang, XiaotianLiang, HanZheng, ZhichaoWang, ZhenningLiu, HaoHu, JiankunSun, YihongZhang, YanqiaoYan, HanTong, LinXu, JiahuiXie, JessicaJi, JiafuShen, Lin
- [9] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialLANCET, 2021, 398 (10294): : 27 - 40Janjigian, Yelena Y.Shitara, KoheiMoehler, MarkusGarrido, MarceloSalman, PamelaShen, LinWyrwicz, LucjanYamaguchi, KenseiSkoczylas, TomaszBragagnoli, Arinilda CamposLiu, TianshuSchenker, MichaelYanez, PatricioTehfe, MustaphaKowalyszyn, RubenKaramouzis, Michalis V.Bruges, RicardoZander, ThomasPazo-Cid, RobertoHitre, ErikaFeeney, KynanCleary, James M.Poulart, ValerieCullen, DanaLei, MingXiao, HongKondo, KaoruLi, MingshunAjani, Jaffer A.
- [10] A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS480 - TPS480Zhen, David BingThota, Ramyadel Corral, ChrisGeng, DongYang, TairanWang, ChuanAmato, GianniAkram, MuhammadMiller, Donna S.Bubuteishvili-Pacaud, LidaGibson, Michael K.